OPTILEUKIN Trademark

Trademark Overview


On Friday, April 25, 2025, a trademark application was filed for OPTILEUKIN with the United States Patent and Trademark Office. The USPTO has given the OPTILEUKIN trademark a serial number of 99151560. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, April 25, 2025. This trademark is owned by InVitria, Inc.. The OPTILEUKIN trademark is filed in the Chemical Products and Pharmaceutical Products categories with the following description:

Recombinant cytokine proteins for clinical or pharmaceutical use; Recombinant cytokine proteins for therapeutic purposes; Recombinant cytokine proteins for the optimization of in vitro expansion of cells; pharmaceutical preparations, namely, cytokine drugs for the optimization of in vitro expansion of cells

Recombinant cytokine proteins for research use; Recombinant cytokine proteins for use in manufacture of pharmaceutical products, veterinary preparations, cellular therapies, gene therapies, regenerative medicines, and vaccines; Chemicals, namely, non-animal derived cell culture media supplement to promote cell growth, optimization, and productivity; non-animal derived cell culture media supplement to promote cell growth, optimization, and productivity for scientific, laboratory or medical research
optileukin

General Information


Serial Number99151560
Word MarkOPTILEUKIN
Filing DateFriday, April 25, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateFriday, April 25, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing0 - NOT AVAILABLE
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Description of MarkThe mark consists of the stylized wording "OptiLeukin" shown with a wave-like design above the wording.
Goods and ServicesRecombinant cytokine proteins for clinical or pharmaceutical use; Recombinant cytokine proteins for therapeutic purposes; Recombinant cytokine proteins for the optimization of in vitro expansion of cells; pharmaceutical preparations, namely, cytokine drugs for the optimization of in vitro expansion of cells
Goods and ServicesRecombinant cytokine proteins for research use; Recombinant cytokine proteins for use in manufacture of pharmaceutical products, veterinary preparations, cellular therapies, gene therapies, regenerative medicines, and vaccines; Chemicals, namely, non-animal derived cell culture media supplement to promote cell growth, optimization, and productivity; non-animal derived cell culture media supplement to promote cell growth, optimization, and productivity for scientific, laboratory or medical research

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateFriday, April 25, 2025
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 25, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameInVitria, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJunction City, KS 66441

Trademark Events


Event DateEvent Description
Friday, April 25, 2025NEW APPLICATION ENTERED
Friday, April 25, 2025APPLICATION FILING RECEIPT MAILED